Spadin
Overview
Spadin is a 17-amino acid peptide derived from the propeptide released during maturation of sortilin, a neurotensin receptor. It functions as an antagonist of the TREK-1 potassium channel, which is implicated in the pathophysiology of major depressive disorder. By blocking TREK-1, spadin increases neuronal excitability and promotes hippocampal neurogenesis, providing a novel antidepressant mechanism distinct from monoaminergic pathways.
Key Research Findings
Preclinical rodent studies have demonstrated rapid antidepressant effects within 4 days of administration, with efficacy comparable to classical antidepressants but with faster onset. Published findings in translational psychiatry journals have shown TREK-1 blockade correlates with increased BDNF expression and synaptic plasticity markers. No clinical trial data in humans have been published to date.
Intravenous, Intranasal
Research Phase
Interested in Spadin?
Find a verified provider experienced with Spadin protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Spadin ProviderRelated Peptides
Semax
FDA ApprovedA synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotective properties. Semax modulates BDNF and NGF expression, enhances monoaminergic neurotransmission, and provides neuroprotection through anti-oxidant and anti-inflammatory mechanisms. It crosses the blood-brain barrier via intranasal administration.
Selank
InvestigationalA synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stability. Selank exhibits anxiolytic activity comparable to benzodiazepines without sedation, dependence, or withdrawal effects. It modulates the expression of BDNF, serotonin, dopamine, and norepinephrine, and influences IL-6 and GABA receptor expression.
Cerebrolysin
InvestigationalA porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors. Cerebrolysin exhibits neurotrophic activity similar to BDNF, GDNF, and CNTF, promoting neuronal survival, synaptic plasticity, and neurogenesis. It modulates GSK-3beta, CDK5, and calcineurin-NFAT signaling cascades involved in neurodegeneration.
P21 (Peptide)
Research PhaseA small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neurogenesis and synaptic plasticity. P21 is a tetrapeptide that crosses the blood-brain barrier and enhances dentate gyrus neurogenesis by increasing BDNF expression. Unlike full-length CNTF, P21 does not activate the JAK-STAT pathway or produce the anorectic and immunogenic effects of the parent protein.